Neonatal Presentation of Ornithine Transcarbamylase Deficiency Associated With a Hypomorphic OTC Variant (p.Leu301Phe) Previously Reported in Later-Onset Disease

Sharon Anderson,Molly Ciarlariello,Christina Botti,Milen Velinov
DOI: https://doi.org/10.7759/cureus.65956
2024-08-01
Cureus
Abstract:Ornithine transcarbamylase deficiency (OTCD) is the most common subtype of urea cycle disorders. Caused by mutations in the X-linked gene OTC,it often leads to hyperammonemia which can result in neurotoxicity, coma, and death. We describe the clinical course of a male newborn known to carry a hypomorphic variant (p.Leu301Phe) in OTC previously reported in cases with later-onset OTCD. Despite being clinically asymptomatic, our affected patient presented with hyperammonemia in the neonatal period. Oral feedings were temporarily discontinued, and low protein medical formula and ammonia scavenger medications were initiated to normalize ammonia levels. This case supports the pathogenicity of the reported OTC gene variant and early presentation that necessitates disease-specific management. Our report will help provide guidance surrounding the most appropriate management of future patients with this variant as they will likely require management in the newborn period.
What problem does this paper attempt to address?